Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib +/- Hydroxychloroquine in EGFR-mutated NSCLC
NCT00977470Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2009
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Oct 2009; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00977470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977470.